Tagged with Inflation Reduction Act

Gilead CEO Named New PhRMA Board Chair; Inherits a Litany of Challenges

USA Gilead CEO Named New PhRMA Board Chair; Inherits a Litany of Challenges

USA The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the industry group’s failed efforts to block the Inflation Reduction Act (IRA) and the departure of several high-profile members. Gilead…

The IRA & Uncertain Times for US Pharma

USA The IRA & Uncertain Times for US Pharma

USA As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market. Drug development is inherently a risky business, but this will compound that risk further… to the point where now,…

Rob Abbott – CEO & Executive Director, ISPOR

Global Rob Abbott – CEO & Executive Director, ISPOR

Global Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of providing quality treatments and services to patients while ensuring that their money is well spent. At the forefront of helping…

Pharma Braces for Widespread Impact of US IRA

USA Pharma Braces for Widespread Impact of US IRA

USA The US Inflation Reduction Act (IRA) passed last year by the Biden administration and hotly contested by the innovative pharma industry, has started to look more like a reality since the first ten drugs subject to price negotiations under the IRA were announced in August. The negotiated prices will not…

The Inflation Reduction Act: What Needs Fixing & What’s Left to Address In Terms of Patient Affordability

USA The Inflation Reduction Act: What Needs Fixing & What’s Left to Address In Terms of Patient Affordability

USA PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to…

Pharma Gets to Grips with the Inflation Reduction Act

USA Pharma Gets to Grips with the Inflation Reduction Act

USA With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new law while deciding how to move forward in response to it. At the recent BIO CEO and Investor Conference, stakeholders…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page